UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Biochemical journal, ISSN 0264-6021, 12/2007, Volume 408, Issue 3, pp. 297 - 315
Drug discovery | Kinase profiling | Protein kinase | Anti-cancer drugs | Inhibitor specificity | Life Sciences & Biomedicine | Biochemistry & Molecular Biology | Science & Technology | Amino Acid Sequence | Cell Line | Phosphorylation | Recombinant Proteins - antagonists & inhibitors | Animals | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Humans | Drug Design | Protein Kinase Inhibitors - pharmacology | Enzyme Activation | Mitogen-Activated Protein Kinases - metabolism | Spodoptera | Index Medicus | Yes1, Yamaguchi sarcoma viral oncogene homologue 1 | CSK, C-terminal Src kinase | Lck, lymphocyte cell-specific protein-tyrosine kinase | EGF, epidermal growth factor | FGF-R, fibroblast-growth-factor receptor | PAK, p21-activated protein kinase | PDK, 3-phosphoinositide-dependent protein kinase | PI3K, phosphatidylinositol (phosphoinositide) 3-kinase | NEK, NIMA (never in mitosis in Aspergillus nidulans)-related kinase | RSK, p90 ribosomal S6 kinase | HEK-293 cells, human embryonic kidney-293 cells | VEGF, vascular endothelial growth factor (vasoendothelial growth factor) | EF2K, elongation-factor-2 kinase | CK, casein kinase | PTEN, phosphatase and tensin homologue deleted on chromosome 10 | ERK, extracellular-signal-regulated kinase | ATM, ataxia telangiectasia mutated | drug discovery | SRPK, serine-arginine protein kinase | IL-1, interleukin 1 | MNK, MAPK-integrating protein kinase | ROCK, Rho-dependent protein kinase | CaMKK, CaMK kinase | GST, glutathione transferase | MKK1, MAPK kinase-1 (also called MEK1, MAPK or ERK kinase 1) | GAK, cyclin G-associated kinase | inhibitor specificity | FMK, fluoromethylketone | MST, mammalian homologue Ste20-like kinase | PKA, cAMP-dependent protein kinase | FKBP, FK506-binding protein | PPAR, peroxisome-proliferator-activated receptor | IKK, inhibitory κB kinase | PH, pleckstrin homology | MBP, myelin basic protein | AICAR, aminoimidazole-4-carboxamide-1-β-D-ribofuranoside | MAPKAP-K, MAPK-activated protein kinase | Sf21, Spodoptera frugiperda (fall armyworm) 21 | MARK, microtubule-affinity-regulating kinase | PIM, provirus integration site for Moloney murine leukaemia virus | LPS, lipopolysaccharide | MSK, mitogen- and stress-activated protein kinase | anti-cancer drugs | MAPK, mitogen-activated protein kinase | MELK, maternal embryonic leucine-zipper kinase | His6, hexahistidine | CAK, cyclin-dependent kinase-activating kinase | Eph-A2, Ephrin A2 receptor | PLK, polo-like kinase | ATF2, activating transcription factor 2 | PKD, protein kinase D | Src, sarcoma kinase | AMPK, AMP-activated protein kinase | MMS, methyl methanesulfonate | CHK, checkpoint kinase | JNK, c-Jun N-terminal kinase | TORC1, mTOR (mammalian target of rapamycin)–raptor (regulatory associated protein of mTOR) complex | protein kinase | BRSK, brain-specific kinase | RIP2, receptor-interacting protein 2 | kinase profiling | IGF-1, insulin-like growth factor-1 | S6K1, S6 kinase 1 | DYRK, dual-specificity tyrosine-phosphorylated and -regulated kinase | HIPK, homeodomain-interacting protein kinase | ZMP, aminoimidazole-4-carboxamide-1-β-D-ribofuranoside monophosphate | PRAK, p38-regulated activated kinase | PKC, protein kinase C | Src-I1, Src inhibitor 1 | TANK, TRAF (tumour-necrosis-factor-receptor-associated factor)-family-member-associated nuclear factor κB activator | NFAT, nuclear factor for activated T-cells | PHK, phosphorylase kinase | GSK3, glycogen synthase kinase 3 | PKB, protein kinase B (also called Akt) | CaMK, calmodulin-dependent kinase | CDK, cyclin-dependent protein kinase | NDRG, N-myc downstream-regulated gene | SmMLCK, smooth-muscle myosin light-chain kinase | TBK1, TANK-binding kinase 1 | PRK, protein kinase C-related kinase | SGK, serum- and glucocorticoid-induced kinase
Journal Article
European journal of haematology, ISSN 0902-4441, 11/2018, Volume 101, Issue 5, pp. 604 - 612
tyrosine kinase expressed in hepatocellular carcinoma (TEC) | platelet | aggregation | Bruton's tyrosine kinase (BTK) | BTK inhibitor | Life Sciences & Biomedicine | Hematology | Science & Technology | Tyrosine | Medicine, Experimental | Phenols | Medical research | Hepatoma | Collagen | Liver cancer | Glycoprotein VI | Hepatocellular carcinoma | Platelet aggregation | Bruton's tyrosine kinase | Protein-tyrosine kinase | Bleeding
Journal Article
The New England journal of medicine, ISSN 0028-4793, 06/2014, Volume 370, Issue 24, pp. 2286 - 2294
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Recurrence | Phospholipase C gamma - metabolism | Pyrazoles - therapeutic use | Humans | Middle Aged | Binding Sites - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Pyrimidines - pharmacology | Receptors, Antigen, B-Cell - metabolism | Sequence Analysis, DNA | Exome | Point Mutation | Drug Resistance, Neoplasm - genetics | Protein-Tyrosine Kinases - genetics | Pyrimidines - therapeutic use | Agammaglobulinaemia Tyrosine Kinase | Phospholipase C gamma - genetics | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Pyrazoles - pharmacology | Tyrosine | Cysteine | Chronic lymphatic leukemia | Serine | Leukemia | Genomes | Lymphatic leukemia | Kinases | Bruton's tyrosine kinase | Lymphocytes B | Mutation | Lymphocytosis | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal of thoracic oncology, ISSN 1556-0864, 03/2013, Volume 8, Issue 3, pp. 346 - 351
Local therapy | Metastasectomy | EGFR-mutant lung cancer | Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors | Respiratory System | Oncology | Life Sciences & Biomedicine | Science & Technology | Bone Neoplasms - mortality | Prognosis | Prospective Studies | Bone Neoplasms - therapy | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Bone Neoplasms - secondary | Lung Neoplasms - pathology | Male | Liver Neoplasms - therapy | Liver Neoplasms - mortality | Brain Neoplasms - secondary | Aged, 80 and over | Adult | Female | Bone Neoplasms - genetics | Brain Neoplasms - mortality | Liver Neoplasms - secondary | Lung Neoplasms - genetics | ErbB Receptors - antagonists & inhibitors | Liver Neoplasms - genetics | Brain Neoplasms - genetics | Survival Rate | Combined Modality Therapy | Lung Neoplasms - therapy | Lymphatic Metastasis | Cranial Irradiation | Mutation - genetics | Drug Resistance, Neoplasm - genetics | Protein Kinase Inhibitors - therapeutic use | Brain Neoplasms - therapy | Aged | Biomarkers, Tumor - genetics | Neoplasm Staging
Journal Article
The lancet oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 747 - 757
d_article_not_yet_freely_accessible | Life Sciences & Biomedicine | Oncology | Science & Technology | Antimitotic agents | Tyrosine | Antineoplastic agents | Analysis | Index Medicus | Life Sciences | Hematology | Human health and pathology | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 05/2009, Volume 119, Issue 5, pp. 1109 - 1123
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Transcription Factor CHOP - genetics | Neoplastic Stem Cells - cytology | Gene Expression - drug effects | Calcium - metabolism | Gene Expression - genetics | Microtubule-Associated Proteins - metabolism | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Endoplasmic Reticulum - metabolism | Antineoplastic Agents - therapeutic use | Autophagy - physiology | Thiazoles - therapeutic use | Autophagy - drug effects | Chloroquine - pharmacology | Neoplastic Stem Cells - metabolism | RNA Interference | Endoplasmic Reticulum - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Macrolides - pharmacology | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Dasatinib | Chloroquine - therapeutic use | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Mice, Inbred C3H | Xenograft Model Antitumor Assays | Fusion Proteins, bcr-abl - genetics | Animals | Cell Death - physiology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Macrolides - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Causes of | Physiological aspects | Genetic aspects | Chronic myeloid leukemia | Research | Drug therapy | Phagocytosis | Index Medicus | Abridged Index Medicus
Journal Article
Clinical cancer research, ISSN 1078-0432, 07/2018, Volume 24, Issue 13, pp. 3097 - 3107
Life Sciences & Biomedicine | Oncology | Science & Technology | Tyrosine | Epidermal growth factor receptors | Lung cancer | Non-small cell lung carcinoma | Drug resistance | Patients | Mutants | Gene sequencing | c-Met protein | Inhibitors | Lungs | Experimental design | Mutation | Pretreatment | Gefitinib | Protein-tyrosine kinase | Cancer | Index Medicus
Journal Article